文献速递中医内科

空间多组学揭示肾化片干预IgA肾病肾皮质代谢重编程机制

Spatially resolved multi-omics reveals the renal cortex-metabolic reprogramming of Shenhua Tablet for intervention on IgA nephropathy.
PubMed 文献 · Phytomedicine · 2025-04-14

本研究采用Thy-1尾静脉注射诱导IgA肾病大鼠模型并给予肾化片干预,结合空间代谢组学与空间转录组学等技术,发现肾化片通过调控谷胱甘肽代谢、糖酵解及L-脯氨酸代谢改善肾损伤,并鉴定芒柄花黄素、毛蕊异黄酮和莪术烯酮为主要活性成分。

要点

  • 肾化片可减轻IgA肾病大鼠炎症及系膜细胞增殖,逆转肾损伤。
  • 肾小管中肾化片逆转Gclc和Gpx3表达调控谷胱甘肽代谢。
  • 肾小球中肾化片下调Oat和Odc1,降低亚精胺和L-脯氨酸抑制系膜细胞增殖。

核心结论

  • 肾化片通过调控谷胱甘肽代谢、糖酵解和L-脯氨酸代谢改善IgA肾病肾损伤。
  • 芒柄花黄素、毛蕊异黄酮和莪术烯酮被鉴定为肾化片主要活性成分并分布于肾皮质。

研究设计与样本

  • 采用Thy-1尾静脉注射诱导IgA肾病大鼠模型并给予肾化片灌胃。
  • 运用经典药理学参数评估肾化片疗效,并结合经典与空间代谢组学检测血清和肾脏代谢物。
  • 采用空间转录组学检测与空间代谢组学相邻肾切片的mRNA水平。
  • 利用质谱成像和细胞实验探究并验证肾化片活性成分。

主要发现

  • 肾化片减轻炎症和系膜细胞增殖,逆转肾损伤。
  • 肾小管中肾化片通过逆转Gclc和Gpx3表达调控谷胱甘肽代谢。
  • 肾小管中Pck1和G6pc1表达增加,抑制糖酵解。
  • 肾小球中肾化片下调Oat和Odc1,降低亚精胺和L-脯氨酸水平,抑制系膜细胞增殖。
  • 芒柄花黄素、毛蕊异黄酮和莪术烯酮被鉴定为肾化片主要活性成分并展示其在肾皮质的分布。

临床怎么用

  • 肾化片可作为IgA肾病临床治疗选择,其机制涉及肾皮质谷胱甘肽代谢、糖酵解及L-脯氨酸代谢调控。
  • 空间多组学策略可为中药复方在组织空间层面的机制研究提供参考。

局限性

  • 早期研究缺乏解剖和代谢数据,阻碍了对肾化片在空间背景下治疗机制的全面理解。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Shenhua tablet (SHT) is a clinically used Chinese patent medicine, which has garnered attention for its effectiveness in treating IgA nephropathy (IgAN). Nevertheless, early researches lacked anatomical and metabolic data, hindering a comprehensive understanding of the therapeutic mechanisms of SHT in spatial contexts. PURPOSE: We aimed to explore the molecular mechanism of SHT intervention in IgAN by utilizing spatial multi-omics strategies. STUDY DESIGN: We injected Thy-1 into tail vein to induce IgAN rat model and administer SHT. Classical pharmacological parameters were used to evaluate the efficacy of SHT. The distribution of active components of SHT and their regulation for metabolites and upstream genes in the cortex were examined to determine the intervention mechanism of SHT. METHODS: After establishing the animal models and administering SHT treatment, Kidney injury were assessed using biochemical indexes and histopathology. Classical and spatial metabolomics were employed to detect metabolites in serum and kidney. Spatial transcriptomics was used to detect mRNA levels in renal sections adjacent to the spatial metabolomics. In addition, mass-spectrometry-imaging and cell experiments were used to explore and verify the active components of SHT. RESULTS: SHT reduced inflammation and mesangial cell proliferation, and reversed kidney damage. Mechanically, in renal tubules, SHT regulated glutathione metabolism by reversing the expression of Gclc and Gpx3. It was further found that Pck1 and G6pc1 were increased to inhibit glycolysis. In glomeruli, SHT downregulated Oat and Odc1 and reduced spermidine and l-proline levels to inhibit mesangial cell proliferation. Finally, formononetin, calycosin and curzerenone were identified as the main active components of SHT and showed their distribution in the cortex. CONCLUSIONS: SHT ameliorated renal injury by regulating glutathione metabolism, glycolysis, and l-proline metabolism, providing a more comprehensive insight into the molecular mechanisms of SHT intervention in IgAN in a spatial context, and offering new perspectives for the treatment of IgAN.

来源:Phytomedicine,查看原文。版权归原作者所有。

引用

  1. Yin F, Li P, Liu C, et al. Spatially resolved multi-omics reveals the renal cortex-metabolic reprogramming of Shenhua Tablet for intervention on IgA nephropathy. Phytomedicine. 2025. PMID: 40233505. doi:10.1016/j.phymed.2025.156742

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。